Inari Medical, Inc. (NARI)
| Market Cap | 4.88B |
| Revenue (ttm) | 110.95M |
| Net Income (ttm) | 7.16M |
| Shares Out | 48.34M |
| EPS (ttm) | 0.15 |
| PE Ratio | 647.49 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $95.86 |
| Previous Close | $95.86 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 94.46 |
| Day's Range | 93.57 - 96.80 |
| Day's Volume | 642,662 |
| 52-Week Range | 42.51 - 96.80 |
IRVINE, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform t...
Inari Medical continues to live up to expectations, showing very solid growth and strong margins. I like the business a lot, yet have not initiated a position yet.
US IPO market activity is picking back up ahead of the Thanksgiving holiday, with six IPOs scheduled to raise $3.4 billion in the week ahead. Biotech research product provider Maravai LifeScie...
There's good reason to think these young stocks have bright futures ahead.
IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform ...
Inari Medical, Inc. (NARI) CEO Bill Hoffman on Q3 2020 Results - Earnings Call Transcript
IRVINE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform ...
IRVINE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform ...
IRVINE, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) announced today that its management team will participate at the Canaccord Genuity Virtual MedTec...
IRVINE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced it will release financial results for the third quarter of 2020 after market clos...
These fast-growing medical device companies could outperform the S&P 500 over the next several years.
IRVINE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transfo...
IRVINE, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transfor...
IRVINE, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform...
Inari Medical, Inc. (NARI) CEO Bill Hoffman on Q2 2020 Results - Earnings Call Transcript
Hot IPO stock Inari Medical late Tuesday reported earnings and sales that beat expectations, but in the regular session shares reversed after hitting an all-time high for a third straight day....
IRVINE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transfor...
IRVINE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced the company will be participating in the upcoming Canaccord Genuity 40th Annual...
IRVINE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced it will release financial results for the second quarter of 2020 after market c...
Its medical devices offer promising clinical benefits over the competition.
IRVINE, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform...
Shares of Inari Medical Inc. NARI, +114.07% rocketed out of the gate Friday, as they opened for trading at prices that were more than double the initial public offering price.
Inari Medical Inc. increased that number of shares it was selling in its initial public offering, which priced late Thursday above the expected range.
About NARI
Inari Medical, a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It produces ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.
| Industry Medical Devices | IPO Date May 22, 2020 |
| CEO William H. Hoffman | Employees 199 |
| Stock Exchange NASDAQ | Ticker Symbol NARI |
Financial Performance
In 2019, Inari Medical's revenue was $51.13 million, an increase of 648.73% compared to the previous year's $6.83 million. Losses were -$1.19 million, -88.26% less than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for Inari Medical stock is "Buy." The 12-month stock price forecast is 91.00, which is a decrease of -5.07% from the latest price.